- Home
- NRT vs CGTX Comparison
NRT vs CGTX Comparison
Compare NRT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRT
- CGTX
- Stock Information
- Founded
- NRT 1975
- CGTX 2007
- Country
- NRT United States
- CGTX United States
- Employees
- NRT N/A
- CGTX N/A
- Industry
- NRT Oil & Gas Production
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- NRT Energy
- CGTX Health Care
- Exchange
- NRT Nasdaq
- CGTX Nasdaq
- Market Cap
- NRT 46.4M
- CGTX 25.1M
- IPO Year
- NRT N/A
- CGTX 2021
- Fundamental
- Price
- NRT $4.91
- CGTX $0.67
- Analyst Decision
- NRT
- CGTX Strong Buy
- Analyst Count
- NRT 0
- CGTX 4
- Target Price
- NRT N/A
- CGTX $2.83
- AVG Volume (30 Days)
- NRT 18.0K
- CGTX 18.6M
- Earning Date
- NRT 08-29-2025
- CGTX 08-07-2025
- Dividend Yield
- NRT 9.78%
- CGTX N/A
- EPS Growth
- NRT 24.05
- CGTX N/A
- EPS
- NRT 0.59
- CGTX N/A
- Revenue
- NRT $6,184,173.00
- CGTX N/A
- Revenue This Year
- NRT N/A
- CGTX N/A
- Revenue Next Year
- NRT N/A
- CGTX N/A
- P/E Ratio
- NRT $8.46
- CGTX N/A
- Revenue Growth
- NRT 18.55
- CGTX N/A
- 52 Week Low
- NRT $3.88
- CGTX $0.22
- 52 Week High
- NRT $6.77
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- NRT 45.60
- CGTX 68.09
- Support Level
- NRT $4.65
- CGTX $0.55
- Resistance Level
- NRT $5.03
- CGTX $1.04
- Average True Range (ATR)
- NRT 0.19
- CGTX 0.10
- MACD
- NRT -0.02
- CGTX 0.02
- Stochastic Oscillator
- NRT 42.82
- CGTX 52.32
About NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.